TCTN3

TCTN3 is a transition-zone component of primary cilia required for ciliogenesis and proper transduction of Sonic Hedgehog (SHH) signaling, where it functions in a complex with TCTN1 and TCTN2 and is needed for correct proteolytic processing of GLI3 (PMID:22883145). Loss of Tctn3 in mice reduces ciliogenesis and Hh signaling and produces developmental patterning defects including holoprosencephaly, randomized heart looping, neural tube defects, and loss of the floor plate; notably, TCTN3 is functionally non-redundant with its paralogs, as only Tctn3 overexpression rescues ciliogenesis in mutant cells (PMID:28800946, PMID:29725084). Mechanistically, Tctn3 disruption depresses the SHH transcriptional output (reduced Gli1 and Ptch1) and triggers neuronal apoptosis through inhibition of PI3K/Akt signaling, a phenotype reversible by Akt activation; TCTN3 forms a protein complex with NPHP1, whose levels fall upon Tctn3 loss (PMID:29725084). Beyond its developmental role, TCTN3 is a transcriptional target of STAT1, which binds the TCTN3 promoter to drive cell-cycle progression, migration, and invasion in papillary thyroid carcinoma, with no direct STAT1-TCTN3 protein interaction (PMID:41581815). Human truncating mutations in TCTN3 underlie a ciliopathy phenotype characterized by abnormal GLI3 processing (PMID:22883145).

1. 2007 Medium

   An early overexpression screen first implicated the uncharacterized C10orf61/TCTN3 gene product in cell-death control, before its ciliary function was known.

   Evidence Transient overexpression in HeLa cells with nuclear morphology imaging, DNA fragmentation ELISA, and caspase-7/PARP cleavage western blots

   PMID:17464193

   Open questions at the time

   • Overexpression context without endogenous loss-of-function validation
   • No link to ciliary or Hedgehog function established at this stage
   • Single lab, single cell line
2. 2012 High

   Identification of truncating TCTN3 mutations in patients established the gene as a transition-zone ciliopathy factor required for SHH transduction, answering whether TCTN3 has a defined developmental signaling role.

   Evidence Homozygosity mapping and exome sequencing in patient families plus GLI3 processing assays in patient cells

   PMID:22883145

   Open questions at the time

   • Molecular basis of TCTN3 contribution to the TCTN1/2/3 complex not resolved
   • Mechanism by which transition-zone localization controls GLI3 processing not defined
3. 2017 High

   Genetic knockout and gene-replacement experiments showed TCTN3 is functionally non-redundant for ciliogenesis and dissected the relationship between ciliogenesis, Hh signaling, and neural tube patterning.

   Evidence Knockout mice, knock-in paralog-replacement, ciliogenesis rescue assays, neural tube patterning analysis, and Gli3 processing western blots

   PMID:28800946

   Open questions at the time

   • Why neural tube patterning and Gli3 repressor formation are preserved upon paralog replacement while ciliogenesis fails is unexplained
   • Structural basis for paralog non-redundancy not determined
4. 2018 High

   A second knockout model connected TCTN3 loss to neuronal apoptosis through PI3K/Akt suppression and identified NPHP1 as a TCTN3 complex partner, linking the ciliary protein to a survival pathway.

   Evidence PiggyBac knockout mice with western blotting, qRT-PCR of Shh targets, immunofluorescence, NPHP1-Tctn3 co-immunoprecipitation, and SC79 pharmacological rescue

   PMID:29725084

   Open questions at the time

   • Direct mechanistic link between TCTN3, NPHP1, and PI3K/Akt activation not defined
   • Whether apoptosis is a direct consequence or downstream of impaired Hh signaling unresolved
5. 2020 Low

   Disease-modeling and cancer studies extended TCTN3 function to cardiomyocyte contractility and to Hedgehog-dependent tumor cell survival.

   Evidence CRISPR-engineered hPSC-derived cardiomyocyte contractility assays; pharmacological suppression of TCTN3 in NSCLC cells with apoptosis and Hh-pathway readouts

   PMID:32456485 PMID:33098376

   Open questions at the time

   • Cardiomyocyte phenotype confounded by a co-occurring LTBP2 mutation
   • NSCLC study uses indirect pharmacological inhibition without genetic TCTN3 knockout or rescue
   • TCTN3 specificity of the cancer phenotype not isolated
6. 2026 Medium

   TCTN3 was placed downstream of a transcriptional regulator, with STAT1 directly activating TCTN3 to drive proliferation and invasion in thyroid carcinoma.

   Evidence ChIP and luciferase reporter assays for promoter binding, negative co-IP for direct interaction, siRNA/overexpression epistasis rescue, multiple proliferation/migration assays, and xenografts

   PMID:41581815

   Open questions at the time

   • Mechanism by which TCTN3 drives cell-cycle and invasion programs downstream of its ciliary role not defined
   • Single lab; generalizability beyond papillary thyroid carcinoma unknown

• How TCTN3's transition-zone scaffolding activity is mechanistically coupled to GLI3 processing, PI3K/Akt-dependent survival, and its non-ciliary oncogenic outputs remains unresolved.
• No structural model of the TCTN1/TCTN2/TCTN3 transition-zone complex in the corpus
• Direct biochemical activity of TCTN3 not established
• Causal chain linking ciliary defects to apoptosis versus tumor-promoting phenotypes not unified